OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CTEC$202.8058

CTEC.L

Medical Equipment, Supplies & DistributionVerified

CTEC.L's capital structure is characterized by a debt-to-equity ratio of 1.0, indicating a balanced mix of debt and equity financing. The company's liquidity position is assessed as medium, with a current ratio of 1.53, suggesting moderate short-term liquidity. However, the company's net cash position is negative after subtracting total debt, which raises concerns about its ability to meet short-term obligations without additional financing. In terms of profitability, CTEC.L's return on equity (ROE) is 11.53%, and its return on assets (ROA) is 4.63%. These figures are relatively strong, but the company's price-to-earnings (P/E) ratio of 2265.39 is significantly higher than typical industry benchmarks, indicating that the stock is highly valued relative to its earnings. The company's gross profit margin is 56.74%, and its operating margin is 12.95%, both of which are key indicators of its operational efficiency. CTEC.L's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration increases the company's exposure to market-specific risks and may limit its growth potential in new regions. The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current fiscal year. The company's free cash flow is $74 million, which is a positive sign for its ability to fund operations and invest in growth opportunities. However, the company's capital expenditure of $185 million indicates a significant investment in infrastructure and expansion. CTEC.L's risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could necessitate additional financing in the future. The company's dilution risk is low, with no significant dilution potential reported in the basic shares outstanding. The company's valuation adjustments do not indicate any material changes to its financial position. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's price targets from analysts range from $250 to $375, with a mean price target of $309.50 and a median price target of $312.50. The mean recommendation from analysts is 1.76, indicating a generally positive outlook.

30-day price · CTEC-42.30 (-17.6%)
Low$195.60High$242.20Close$198.30As of28 May, 00:00 UTC
Profile
CompanyCTEC.L
TickerCTEC.L
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. CTEC.L provides medical equipment, supplies, and distribution services within the healthcare sector.

Classification. CTEC.L is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

CTEC.L's capital structure is characterized by a debt-to-equity ratio of 1.0, indicating a balanced mix of debt and equity financing. The company's liquidity position is assessed as medium, with a current ratio of 1.53, suggesting moderate short-term liquidity. However, the company's net cash position is negative after subtracting total debt, which raises concerns about its ability to meet short-term obligations without additional financing. In terms of profitability, CTEC.L's return on equity (ROE) is 11.53%, and its return on assets (ROA) is 4.63%. These figures are relatively strong, but the company's price-to-earnings (P/E) ratio of 2265.39 is significantly higher than typical industry benchmarks, indicating that the stock is highly valued relative to its earnings. The company's gross profit margin is 56.74%, and its operating margin is 12.95%, both of which are key indicators of its operational efficiency. CTEC.L's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration increases the company's exposure to market-specific risks and may limit its growth potential in new regions. The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current fiscal year. The company's free cash flow is $74 million, which is a positive sign for its ability to fund operations and invest in growth opportunities. However, the company's capital expenditure of $185 million indicates a significant investment in infrastructure and expansion. CTEC.L's risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could necessitate additional financing in the future. The company's dilution risk is low, with no significant dilution potential reported in the basic shares outstanding. The company's valuation adjustments do not indicate any material changes to its financial position. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's price targets from analysts range from $250 to $375, with a mean price target of $309.50 and a median price target of $312.50. The mean recommendation from analysts is 1.76, indicating a generally positive outlook.
Key takeaways
  • CTEC.L has a balanced capital structure with a debt-to-equity ratio of 1.0.
  • The company's ROE of 11.53% and ROA of 4.63% indicate strong profitability.
  • CTEC.L's revenue is concentrated in a single business segment, increasing its exposure to market-specific risks.
  • The company's liquidity position is assessed as medium, with a current ratio of 1.53.
  • Analysts have a generally positive outlook on CTEC.L, with a mean price target of $309.50.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$2.44B
Gross profit$1.38B
Operating income$316.0M
Net income$175.0M
R&D
SG&A
D&A
SBC
Operating cash flow$470.0M
CapEx-$185.0M
Free cash flow$74.0M
Total assets$3.78B
Total liabilities$2.26B
Total equity$1.52B
Cash & equivalents$68.0M
Long-term debt$1.52B
Valuation
Market price$202.80
Market cap$396.44B
Enterprise value$397.89B
P/E2265.4
Reported non-GAAP P/E
EV/Revenue163.1
EV/Op income1259.2
EV/OCF846.6
P/B261.2
P/Tangible book261.2
Tangible book$1.52B
Net cash-$1.45B
Current ratio1.5
Debt/Equity1.0
ROA4.6%
ROE11.5%
Cash conversion2.7%
CapEx/Revenue-7.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricCTECActivity
Op margin13.0%3.9% medp25 -31.3% · p75 14.4%above median
Net margin7.2%2.4% medp25 -30.5% · p75 11.1%above median
Gross margin56.7%46.7% medp25 28.2% · p75 63.1%above median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-7.6%-4.8% medp25 -11.6% · p75 -2.4%below median
Debt / equity100.0%17.9% medp25 2.7% · p75 52.2%top quartile
Observations
IR observations
Mean price target309.50 USD
Median price target312.50 USD
High price target375.00 USD
Low price target250.00 USD
Mean recommendation1.76 (1=strong buy, 5=strong sell)
Strong-buy count5.00
Buy count11.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.20 USD
Last actual EPS0.18 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 18:39 UTC#cd38a256
Market quoteclose USD 213.00 · shares 1.95B diluted
no public URL
2026-05-06 18:39 UTC#a0470901
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 17:23 UTCJob: b4f5cac2